Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5887 - Retrospective analysis of the treatment of metastatic uveal melanoma comparing systemic chemotherapy and transarterial chemoembolization

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy

Tumour Site

Melanoma

Presenters

Caroline Anna Peuker

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

C.A. Peuker1, L. Polzin2, S. Ochsenreither3, M. De Bucourt4, S. Leyvraz1, U. Keilholz5, A. Joussen6, J. Eucker7

Author affiliations

  • 1 Medical Oncology, Haematology And Tumor Immunology, Charité Comprehensive Cancer Center, 10117 - Berlin/DE
  • 2 Department Of Haematology And Medical Oncology, Campus Benjamin Franklin, Berlin, Germany, Charité - University Medicine Berlin, 12200 - Berlin/DE
  • 3 Charité Comprehensive Cancer Center, Charité University of Medicine, 10117 - Berlin/DE
  • 4 Department Of Radiology, Campus Benjamin Franklin, Berlin, Germany, Charité - University Medicine Berlin, 12200 - Berlin/DE
  • 5 Oncology, Charite Comprehensive Cancer Center, 10117 - Berlin/DE
  • 6 Department Of Ophthalmology, Campus Benjamin Franklin, Berlin, Germany, Charité - University Medicine Berlin, 12200 - Berlin/DE
  • 7 Medizinische Klinik M. S. Hämatologie Und Onkologie, Charite, Campus Benjamin Franklin Medizinische Klinik III, 12200 - Berlin/DE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5887

Background

Metastatic uveal melanoma (mUM) is a rare disease with poor prognosis, hardly responding to systemic treatment. As the liver is the most common and prognostic relevant metastatic site, liver-directed therapies have come into focus.

Methods

A retrospective analysis was carried out in patients who were treated at our center between 2008 and 2017 receiving chemotherapy (1000 mg/m2 gemcitabine + 3500 mg/m2 treosulfan (GeT) on days 1 + 8, 4-week cycles) or transarterial chemoembolization (TACE, EmboCept® S microspheres + 50 mg cisplatin, every 4-6 weeks) as 1st-line therapy for mUM.

Results

287 patients were treated for mUM in the time period, 93 received TACE and 82 GeT as 1st-line therapy. Patient characteristics differed in the metastatic pattern: patients receiving GeT having a significant higher rate of non-liver dominant metastatic disease compared to the TACE group (p < 0.001), whereas there was no difference in age, sex, DFI, laboratory values and percentage of liver involvement. Median overall survival (OS) in the GeT group was 11.3 vs. 8.4 months in the TACE group (p = 0.089), with a median progression-free survival (PFS) of 2.7 and 2.8 months respectively (ns). Overall response rate for GeT was 6.8% and disease control rate was 41.1%, for TACE 10.2% and 47.7% respectively (both ns). Age, sex, baseline laboratory values, PFS and percentage of liver involvement were significantly associated with OS in univariate analysis. Multivariate Cox regression analysis identified male sex, elevated bilirubin, GGT, ALP, percentage of liver involvement >50% and PFS ≤2.7 months as significant independent prognostic factors for shorter survival. The metastatic pattern and the type of treatment did not show to be significant prognostic factors.

Conclusions

Liver-directed therapies can improve response rates compared to systemic therapies and should be preferred in patients with liver-dominant metastatic pattern. However, PFS and OS remain poor and not significantly different between intrahepatic and systemic therapies. Further research should focus on developing new therapies based on a better understanding of the biology of these tumors.

Clinical trial identification

Legal entity responsible for the study

Charité Comprehensive Cancer Center, Charité - University Medicine Berlin.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.